Current Biomedical Use of Copper Chelation Therapy
- PMID: 32041110
- PMCID: PMC7037088
- DOI: 10.3390/ijms21031069
Current Biomedical Use of Copper Chelation Therapy
Abstract
Copper is an essential microelement that plays an important role in a wide variety of biological processes. Copper concentration has to be finely regulated, as any imbalance in its homeostasis can induce abnormalities. In particular, excess copper plays an important role in the etiopathogenesis of the genetic disease Wilson's syndrome, in neurological and neurodegenerative pathologies such as Alzheimer's and Parkinson's diseases, in idiopathic pulmonary fibrosis, in diabetes, and in several forms of cancer. Copper chelating agents are among the most promising tools to keep copper concentration at physiological levels. In this review, we focus on the most relevant compounds experimentally and clinically evaluated for their ability to counteract copper homeostasis deregulation. In particular, we provide a general overview of the main disorders characterized by a pathological increase in copper levels, summarizing the principal copper chelating therapies adopted in clinical trials.
Keywords: cancer; chelation therapy; copper; metal homeostasis; metalloproteins; therapeutic chelation.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures
Similar articles
-
Selective divalent copper chelation for the treatment of diabetes mellitus.Curr Med Chem. 2012;19(17):2828-60. doi: 10.2174/092986712800609715. Curr Med Chem. 2012. PMID: 22455587 Review.
-
Copper in medicine: homeostasis, chelation therapy and antitumor drug design.Curr Med Chem. 2006;13(5):525-37. doi: 10.2174/092986706776055742. Curr Med Chem. 2006. PMID: 16515519 Review.
-
Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.Drugs. 2011 Jul 9;71(10):1281-320. doi: 10.2165/11591370-000000000-00000. Drugs. 2011. PMID: 21770477 Review.
-
Chelating agents for neurodegenerative diseases.Curr Med Chem. 2012;19(17):2760-72. doi: 10.2174/092986712800609689. Curr Med Chem. 2012. PMID: 22489724 Review.
-
Copper chelation as an antiangiogenic therapy.Oncol Res. 2004;14(11-12):529-39. doi: 10.3727/0965040042707952. Oncol Res. 2004. PMID: 15666995 Review.
Cited by
-
New prospectives on treatment opportunities in RASopathies.Am J Med Genet C Semin Med Genet. 2022 Dec;190(4):541-560. doi: 10.1002/ajmg.c.32024. Epub 2022 Dec 19. Am J Med Genet C Semin Med Genet. 2022. PMID: 36533679 Free PMC article. Review.
-
Analyzing the Therapeutic Efficacy of Bis-Choline-Tetrathiomolybdate in the Atp7b-/- Copper Overload Mouse Model.Biomedicines. 2021 Dec 8;9(12):1861. doi: 10.3390/biomedicines9121861. Biomedicines. 2021. PMID: 34944677 Free PMC article.
-
Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers.Polymers (Basel). 2021 Nov 17;13(22):3969. doi: 10.3390/polym13223969. Polymers (Basel). 2021. PMID: 34833268 Free PMC article. Review.
-
Trace Elements in Medicinal Metallomics.Mini Rev Med Chem. 2025;25(9):664-674. doi: 10.2174/0113895575333766240912162252. Mini Rev Med Chem. 2025. PMID: 39323348 Review.
-
Evolving approaches in glioma treatment: harnessing the potential of copper metabolism modulation.RSC Adv. 2023 Nov 21;13(48):34045-34056. doi: 10.1039/d3ra06434d. eCollection 2023 Nov 16. RSC Adv. 2023. PMID: 38020008 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
